

Lactococcus lactis: A New Strategy for Vaccination

Maryam Azizpour¹, Seyyed Davood Hosseini^{2*}, Parvaneh Jafari³, and Neda Akbary³

1- Department of Microbiology, Arak branch, Islamic Azad University, Arak, Iran

2- Razi Vaccine and Serum Research Institute, Arak Branch, Arak, Iran

3- Department of Microbiology, Islamic Azad University, Arak Branch, Arak, Iran

* **Corresponding author:**
Seyyed Davood Hosseini, Ph.D.,
Razi Vaccine and Serum
Research Institute, Arak, Iran
Tel: +98 86 33544702
Fax: +98 86 33544704
E-mail:
hosseinida@yahoo.com
Received: 29 Jun 2016
Accepted: 5 Dec 2016

Abstract

Needle free vaccines have a several advantages and very attractive way for vaccination. In a body, mucosal surfaces provide a universal entry portal for all the known and emerging infectious pathogenic microbes. Therefore, it seems, vaccination strategies need to be reorganized for vaccines that are hindering the entry capability of pathogenic microbes through mucosal surfaces. Lactic acid Bacteria (LAB) are widely used in the food industry and at the present, used as delivery vehicles for biological investigations. In this review, we summarized the Results of several studies which *Lactococcus lactis* (*L. lactis*) used as a live vector for vaccines. These bacteria are considered as promising candidates for heterologous expression of proteins and biotechnological usage. LAB are considered as promising candidates for heterologous expression of proteins and biotechnological usage. The results showed that these bacteria have an ability to deliver antigen to immune system. Therefore, developing mucosal live vaccines using lactic acid bacterium, *L. lactis*, as an antigen delivery vector, is an attractive alternative choice and a safer vaccination strategy against pathogens.

Avicenna J Med Biotech 2017; 9(4): 163-168

Keywords: DNA, *Lactococcus lactis*, Vaccines

Introduction

In 1980, Walter Schaffner demonstrated that the bacteria are able to transfer genetic material into mammalian cells *in vitro*. So, they suggested new vectors for plasmid vaccines transfer¹⁻³. Later, it was shown that the gram-positive bacteria like *Listeria monocytogenes* are capable of conveying DNA plasmid⁴. Since then, attenuated or artificially engineered invasive bacteria have been tested as a vehicle for transgene delivery⁵.

For centuries, people have recognized that the consumption of fermented products can have a positive effect on human health. Over decades, it has become clear that these probiotic, Lactic Acid Bacteria (LAB) are classified as safe GRAS by the United States Food and Drug Administration (USFDA)⁶. Moreover, a number of LAB can induce the immune system response like adjuvants, because of their probiotic properties and their capacity for inducing the host immune system⁷. While commensal and pathogenic bacteria as a mucosal delivery vehicles have benefits and drawbacks, lactic acid bacteria are more desirable for their safety and lower side effects⁸.

Lactococcus lactis (*L. lactis*) with a good history of safety in food fermentation and the ability to survive in passage through the gastrointestinal tract of animals and humans⁹ (until now, with a 2 to 3 days survival

time) does not invade or colonize the mucosal surfaces of the host. Furthermore, *L. lactis* does not have lipopolysaccharides and for this reason, does not stimulate host immune responses powerfully¹⁰⁻¹². Because of the progress in many genetic tools and sequenced complete genome, it is easier for researchers to manipulate the gene and produce proteins to the host mucosal surfaces, *via* the oral, genital or intranasal¹²⁻¹⁵. Now, many studies are designed which use recombinant *L. lactis* to stimulate an immune response against various antigens⁹.

In this paper, the ability of *L. lactis* to transfer antigenic and therapeutic proteins was described. For this purpose, first, the interaction between *L. lactis* and host gastrointestinal mucosal tract was explained. So, new investigations which use the recombinant *L. lactis* as a mucosal vaccine were reviewed. Eventually, some early outcomes of such antigen producing bacteria were included in this study in order to pave the way for future developments.

L. lactis and host interaction

Microfold (M) cells have a significant role in inducing mucosal immune response and perpetuity of the mucosal surface barrier. M cells transfer pathogens and foreign molecules from apical lumen side to basal side *via* using transcytosis. M cells do not have a mucus




Figure 1. Schematic representation of Peyer's patches, M cells, and the different immune cell populations. M cells have no mucus. IFR: intra-follicular region, B: B cells, IEL: intraepithelial lymphocyte, T: T cells, FoDC: follicular dendritic cell, DC: dendritic cells.

layer on their apical side^{5,16}. This character allows M cells to uptake antigens efficiently from the luminal space. The basal side of M cells, which formed from invaginated membranes, has pockets and house Dendritic Cells (DCs) (Figure 1). These DCs take up transported pathogens and molecules and help to manage the adaptive immune response¹⁷. This close vicinity of DCs to M cells is especially remarkable because of the rapid process of the transcytosed antigens and presentation of antigenic peptides to B and T cells for inducing immune responses. Germinal center contains a network of follicular dendritic cells and many B cells, IgA-producing B cells¹⁶. These B cells can migrate into the intestinal lamina propria and secrete IgA (sIgA, Figure 1). The space between neighborhood follicles in the Peyer's Patches (PPs) is called Intrafollicular Region (IFR). The IFR is full of T cells and DCs and helps to administer the adaptive immune response in the PPs¹⁸. *L. lactis* enters through Intestinal Epithelial Cells (IECs) or M cells, so internalizes and reproduces within phagocytic cells, and causes cellular death mechanism used to spread to a deeper layer. In a usual manner, inflammatory response induced and infiltration of polymorphonuclear cells occurred cause the activation of inflammatory cascades and produce pro-inflammatory cytokines and severe tissue damages. So, the microbes from infected lesions were cleared and the production of antimicrobial neutralizing antibodies occurred. Thus, a dynamic immune network with native and acquired mucosal responses was created¹⁹⁻²¹.

***L. lactis* as a live vehicle for mucosal vaccine delivery**

Developing the molecular ways and genetic manipulating to effectively produce antigens and curative molecules in various cells to deliver protein and DNA to host cells was important to present LAB as a live vehicle. A remarkable property of genetically-engineered LAB is that mucosal administration elicits both systemic and mucosal immunity¹². In LAB, a hopeful candidate for vaccines development is *L. lactis* because

(1) various genetic ways have been developed for it, (2) its genome is completely sequenced, (3) and its safety property has been revealed. Iwaki *et al* in 1990 attempted to use *L. lactis* as a live vaccine²². Many investigations with recombinant *L. lactis* strains have been performed and protection or incomplete protection was observed²³. Lately, LAB as a live vehicle has been investigated in different studies²⁴⁻²⁶. In this study, some recent studies for using LAB as a vaccine are included.

Results

The first investigation for *L. lactis* based mucosal vaccine was against the *Streptococcus mutans* surface protein (Pac). When cytoplasm expressed this gene in *L. lactis* and supplied orally the killed bacteria, the valuable responses of IgA and IgG were seen²². In addition, next studies on *Clostridium tetani* toxin, fragment C (TTFC-Tetanus Toxin Fragment C) with *L. lactis* strain showed the highly immunogenic property^{6,27}. Studies showed that the nasal route of surface which displayed recombinant TTFC was preferred²⁸. The intracellularly expressed T3SS (type III secretory system protein) vaccines against EspB which were orally used, after ten days, have no particular serum and faecal antibodies. Besides, in BALB/c mice, intraperitoneal vaccination of the EspB protein increases serum IgG and faecal IgA levels²⁹. The comparative efficacy was explored when given orally and intramuscularly in piglets³⁰. The intramuscular inoculation with recombinant *L. lactis* producing FaeG (fimbria adhesion) can stimulate a specific systemic response. In another study, nasal inoculation with recombinant *L. lactis* expressing a conserved stretch peptide of the avian influenza M2 antigen in birds can increase survival times against high pathogenic avian influenza virus A subtype H5N2³¹.

In another challenge on mice, nasal and Bronchoalveolar Lavages (BAL) inoculation with recombinant *L. lactis* expressing *Brucella abortus* (*B. abortus*) Cu-Zn Superoxide Dismutase (SOD), showed SOD-specific IgM and SOD-specific sIgA antibodies which protected the mice against virulent *B. abortus* strain⁹. Oral and intra-nasal vaccination with *L. lactis* strain expressing *Rhodococcus equi* (*R. equi*) VapA (virulence-associated protein A) in mice led to a specific mucosal immune response against VapA in a challenge with a virulent strain of *R. equi*³². In another investigation, intragastric route vaccination with recombinant *L. lactis* producing VP7 could induce systemic IgG antibody response against rotavirus³³. So, mice orally administered with recombinant *L. lactis* producing intracellular rotavirus spike-protein subunit VP8, showed the significant levels of intestinal IgA antibodies, while the secreted cytoplasm expressed protein or as a surface-anchored antigen induced anti-VP8 antibodies at both mucosal and systemic levels³⁴. Oral administration of recombinant *L. lactis* producing enterotoxin B

Table 1. *L. lactis* strains and plasmids for expression

Strains	Strains property	Plasmids	Plasmids property	Reference
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8008	Reference plasmid for nisin, intracellular expression	[42, 47]
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8148	Cm ^R . intracellular expression	[42]
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8150	Cm ^R . intracellular expression	[42]
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ9530	low copy plasmid, intracellular expression	[42, 46]
<i>L. lactis</i> NZ3000	acF ⁻ of strain MG5267	pNZ8149	lacF ⁺ . food grade, intracellular expression	[44, 48]
<i>L. lactis</i> NZ3900	lacF ⁻ , pepN: nisRK, food grade	pNZ8149	lacF ⁺ . food grade, intracellular expression	[44, 48]
<i>L. lactis</i> NZ3910	Same as but nisRnisK integrated into a neutral locus	pNZ8149	lacF ⁺ . food grade, intracellular expression	[49, 48]
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8120	Cm ^R . NICE Secretion vectors	[50]
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8121	Cm ^R . NICE Secretion vectors	[50], unpublished
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8122	Cm ^R . NICE Secretion vectors	[51]
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8123	Cm ^R . NICE Secretion vectors	unpublished
<i>L. lactis</i> NZ9000/NZ9100	Refer text	pNZ8124	Cm ^R . NICE Secretion vectors	[52], unpublished
<i>L. lactis</i> NZ3900/NZ3910	Refer Table 1	pNZ8151	lacF ⁺ . food grade, intracellular expression	[42]
<i>L. lactis</i> NZ9130	alr-, nisRK	pNZ8152	lacF ⁺ . food grade, intracellular expression	[49, 42]

Cm^R: Chloramphenicol resistance.

of *Staphylococcus aureus* (*S. aureus*) in mice elicited cellular or systemic immune responses and increased survival rate in vaccinated mice against *S. aureus*¹⁴. Moreover, vaccination of animal with *L. lactis* expressed papillomavirus type16 (HPV16) E7 protein, persuasion of humoral and cellular immune responses and protected the animals against HPV-16 induced tumors³⁴. In mice, intranasal administration of recombinant *L. lactis* strain expressing *Yersinia pseudotuberculosis* Low-calcium response V (LcrV) antigen was able to elicit specific systemic and mucosal antibody and cellular immune responses against *Yersinia* infection. This investigation revealed that the type of antigen and administration place of vaccine are very important which can have an effect on antigen-specific immune responses^{35,36}. These studies are very valuable for the probability in applying vaccination or therapy with recombinant *L. lactis* because of their capacity for inducing mucosal and systemic immune responses^{37,38}.

Few general strains of *L. lactis* and plasmids

NZ9000 is the usual standard host strain for nisin regulated gene expression (NICE®). Moreover, in this bacteria, nisK and nisR genes were cloned into the pepN gene of MG1363³⁹. In the strain NZ9100, nisin genes were inserted into a neutral locus. All used strains were obtained from *L. lactis* subsp. *cremoris* MG1363.

In pNZ8008, pNZ8148, pNZ8149, and pNZ8150 vectors, replicon was the same and arose from pSH71 plasmid of *L. lactis*. These plasmids can be multiplied in various gram-positive bacteria, for example, *Streptococcus thermophilus* and *Lactobacillus plantarum* (*L. plantarum*) and they replicate in *Escherichia coli* (*E. coli*), but need a recA+strain like MC1061. The pNZ8149 vector contains the lacF gene as a food grade selection marker. In such vectors for transformation

process, a host strain, such a *L. lactis* NZ3900, which has lactose operon and lacks lacF gene, was necessary^{40,41}. In pNZ9530, the replication genes came from *Enterococcus faecalis* pAMB1 plasmid which replicate only in gram-positive bacteria, like, *L. lactis* and *L. plantarum*^{42,43}. In table 1, common host strains and plasmids are summarized.

Safety concerns

The potential risk of using lactic acid bacteria based mucosal vaccines is the entry of the genetically manipulated creatures to the environment. The manipulated bacteria which produce antigens and antibiotic markers may lead to the horizontal transfer of plasmid to other bacteria. Therefore, the auxotrophic mutants which are unable to multiply in the environment were designed. For this reason, in *L. lactis*, scientists substituted the thyA gene (thymidylate synthase) with the human IL-10 and made an auxotrophic strain which could not survive in an environment without thymidine⁴⁴. So, a recombinant *L. lactis* was made which contained LLO (Listeriolysin O of *Listeria monocytogenes*) gene. Therefore, such bacteria not only need a vector with antibiotic markers but also minimize the probability of gene transfer to another bacteria in the environment⁴⁵. Also, a novel vaccination method was the external linkage of ARV (avian retro virus) sigma C to LAB cell wall. When this antigen was cloned in *E. coli* and conjugated on the surface of *Enterococcus faecium*, it induced mucosal and systemic immunity in mouse⁴⁶.

Conclusion

A big concern about the use of live LAB mucosal vaccines was the risk of transmission of genetically manipulated creatures to nature. So, the use of auxotrophic mutants can prevent the reproduction of such organisms in the environment. Also, food grade plas-

mids and auxotrophic strains can be used for solving the problem about the horizontal transfer of plasmids which carry antibiotic resistance markers to the environmental and host microflora.

In this paper, some LAB mucosal vaccines were reviewed which had some advantages in comparison to injected vaccines: (a) their ability to induce the systemic and mucosal immune responses in the host cell, (b) their easy manipulation (c) not requiring expert personnel. Moreover, its safety concerns about releasing recombinant plasmids and chromosomally modified bacterial strains in the environment can be controlled. So, lactic acid bacteria are very good mucosal delivery vectors for heterologous antigens and can be used in clinical trials. The studies revealed that recombinant *L. lactis* can stimulate mucosal immunity response. So, vaccination or therapy strategy with these bacteria is valuable.

Acknowledgement

The authors thank Dr. Hosseini, the head of Razi vaccine and serum Research institute, Arak Branch, Dr. Jafari, Department of Microbiology, Islamic Azad University, Arak Branch, Arak, Iran, Dr. Akbary, Department of Microbiology, Islamic Azad University, Arak Branch, Arak, Iran for their constant support, guidance and inspiration.

References

1. Grillot-Courvalin C, Goussard S, Huetz F, Ojcius DM, Courvalin P. Functional gene transfer from intracellular bacteria to mammalian cells. *Nat Biotechnol* 1998;16: 862-866.
2. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated shigella as a DNA delivery vehicle for DNA-mediated immunization. *Science* 1995;270(5234):299-302.
3. Vassaux G, Nitcheu J, Jezzard S, Lemoine NR. Bacterial gene therapy strategies. *J Pathol* 2006;208(2):290-298.
4. Becker PD, Noerder M, Guzmán CA. Genetic immunization: bacteria as DNA vaccine delivery vehicles. *Hum Vaccin* 2008;4(3):189-202.
5. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. *Mol Ther* 2009;17(5):767-777.
6. Pellissery AJ, Nair UR. Lactic acid bacteria as mucosal delivery vaccine. *Adv Anim Vet Sci* 2013;1(6):183-187.
7. Seegers JF. Lactobacilli as live vaccine delivery vectors: progress and prospects. *Trends Biotechnol* 2002;20(12): 508-515.
8. del Rio B, Dattwyler RJ, Aroso M, Neves V, Meirelles L, Seegers JF, et al. Oral immunization with recombinant *Lactobacillus plantarum* induces a protective immune response in mice with Lyme disease. *Clin Vaccine Immunol* 2008;15(9):1429-1435.
9. Sáez D, Fernández P, Rivera A, Andrews E, Oñate A. Oral immunization of mice with recombinant *Lactococcus lactis* expressing Cu,Zn superoxide dismutase of *Brucella abortus* triggers protective immunity. *Vaccine* 2012; 30(7):1283-1290.
10. Siezen RJ, Kok J, Abee T, Schafsma G. Lactic acid bacteria: genetics, metabolism and applications. *Antonie Van Leeuwenhoek* 2002;82(1-4):1.
11. Gui-hua W, Xi-lin H, Li-yun Y, Jian-kui L, Chun-hua W. Studies on mucosal Immunity Induced by transmissible gastroenteritis virus nucleocapsid protein recombinant *Lactobacillus casei* in mice and sow. *Agric Sci China* 2009;8(2):231-237.
12. D'Souza R, Pandeya DR, Hong ST. *Lactococcus lactis*: an efficient gram positive cell factory for the production and secretion of recombinant protein. *Biomed Res* 2012; 23(1):1-7.
13. Wyszynska A, Kobierecka P, Bardowski J, Jagusztyn-Krynicka EK. Lactic acid bacteria--20 years exploring their potential as live vectors for mucosal vaccination. *Appl Microbiol Biotechnol* 2015;99(7):2967-2977.
14. Asensi GF, de Sales NF, Dutra FF, Feijó DF, Bozza MT, Ulrich RG, et al. Oral immunization with *Lactococcus lactis* secreting attenuated recombinant staphylococcal enterotoxin B induces a protective immune response in a murine model. *Microb Cell Fact* 2013;12:32.
15. Bermúdez-Humarán LG, Kharrat P, Chatel JM, Langella P. Lactococci and lactobacilli as mucosal delivery vectors for therapeutic proteins and DNA vaccines. *Microb Cell Fact* 2011;10 Suppl 1:S4.
16. Mestecky J, Strober W, Russell M, Cheroutre H, Lambrecht BN, Kelsall B. *Mucosal immunology*. 4th ed. USA: Academic Press; 2015. 2064 p.
17. Yamamoto M, Pascual DW, Kiyono H. M cell-targeted mucosal vaccine strategies. *Curr Top Microbiol Immunol* 2012;354:39-52.
18. Shakya AK, Chowdhury MY, Tao W, Gill Hs. Mucosal vaccine delivery: current state and a pediatric perspective. *J Control Release* 2016;240:394-413.
19. Adachi K, Kawana K, Yokoyama T, Fujii T, Tomio A, Miura S, et al. Oral immunization with a *Lactobacillus casei* vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. *Vaccine* 2010; 28(16):2810-2817.
20. Bermúdez-Humarán LG. *Lactococcus lactis* as a live vector for mucosal delivery of therapeutic proteins. *Hum Vaccin* 2009;5(4):264-267.
21. Lebeer S, Vanderleyden J, Keersmaecker SC. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. *Nat Rev Microbiol* 2010;8(3):171-184.
22. Iwaki M, Okahashi N, Takahashi I, Kanamoto T, Sugita-Konishi Y, Aibara K, et al. Oral immunization with recombinant *Streptococcus lactis* carrying the *Streptococcus mutans* surface protein antigen gene. *Infect Immun* 1990;58(9):2929-2934.
23. Pontes DS, de Azevedo MS, Chatel JM, Langella P, Azevedo V, Miyoshi A. *Lactococcus lactis* as a live vector: heterologous protein production and DNA delivery systems. *Protein Expr Purif* 2011;79(2):165-175.
24. Guimarães VD, Innocentini S, Lefèvre F, Azevedo V, Wal JM, Langella P, et al. Use of native lactococci as

- vehicles for delivery of DNA into mammalian epithelial cells. *Appl Environ Microbiol* 2006;72(11):7091-7097.
25. Chatel JM, Pothelune L, Ah-Leung S, Corthier G, Wal JM, Langella P. In vivo transfer of plasmid from food-grade transiting lactococci to murine epithelial cells. *Gene Ther* 2008;15(16):1184-1190.
 26. Tao L, Pavlova SI, Ji X, Jin L, Spear G. A novel plasmid for delivering genes into mammalian cells with noninvasive food and commensal lactic acid bacteria. *Plasmid* 2011;65(1):8-14.
 27. Wells JM, Wilson PW, Norton PM, Gasson MJ, Le Page RW. *Lactococcus lactis*: high-level expression of tetanus toxin fragment C and protection against lethal challenge. *Mol Microbiol* 1993;8(6):1155-1162.
 28. Nouaille S, Ribeiro LA, Miyoshi A, Pontes D, Le Loir Y, Oliveira SC, et al. Heterologous protein production and delivery systems for *Lactococcus lactis*. *Genet Mol Res* 2003;2(1):102-111.
 29. Ahmed B, Loos M, Vanrompay D, Cox E. Mucosal priming of the murine immune system against enterohemorrhagic *Escherichia coli* O157:H7 using *Lactococcus lactis* expressing the type III secretion system protein EspB. *Vet Immunol Immunopathol* 2013;152(1-2):141-145.
 30. Liu S, Li Y, Xu Z, Wang Y. Subcutaneous or oral Immunization of mice with *Lactococcus lactis* expressing F4 fimbrial adhesin FaeG. *J Vet Med Sci* 2013;75(6):779-784.
 31. Ferbas J, Belouski SS, Horner M, Kaliyaperumal A, Chen L, Boyce M, et al. A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus. *Br J Clin Pharmacol* 2013;76(2):188-202.
 32. Cauchard S, Bermúdez-Humarán LG, Blugeon S, Laugier C, Langella P, Cauchard J. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against *Rhodococcus equi* infection. *Vaccine* 2011;30(1):95-102.
 33. Marelli B, Perez AR, Banchio C, de Mendoza D, Magni C. Oral immunization with live *Lactococcus lactis* expressing rotavirus VP8 subunit induces specific immune response in mice. *J Virol Methods* 2011;175(1):28-37.
 34. Bermúdez-Humarán LG, Cortes-Perez NG, Lefèvre F, Guimarães V, Rabot S, Alcocer-Gonzalez JM, et al. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. *J Immunol* 2005;175(11):7297-7302.
 35. Cortes-Perez NG, Lefèvre F, Corthier G, Adel-Patient K, Langella P, Bermúdez-Humarán LG. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. *Vaccine* 2007;25(36):6581-6588.
 36. Daniel C, Sebbane F, Poiret S, Goudercourt D, Dewulf J, Mullet C, et al. Protection against *Yersinia pseudotuberculosis* infection conferred by a *Lactococcus lactis* mucosal delivery vector secreting LcrV. *Vaccine* 2009;27(8):1141-1144.
 37. Xin KQ, Hoshino Y, Toda Y, Igimi S, Kojima Y, Jounai N, et al. Immunogenicity and protective efficacy of orally administered recombinant *Lactococcus lactis* expressing surface-bound HIV Env. *Blood* 2003;102(1):223-228.
 38. Robinson K, Chamberlain LM, Lopez MC, Rush CM, Marcotte H, Le Page RW, et al. Mucosal and cellular immune responses elicited by recombinant *Lactococcus lactis* strains expressing tetanus toxin fragment C. *Infect Immun* 2004;72(5):2753-2761.
 39. Mierau I, Kleerebezem M. 10 years of the nisin-controlled gene expression system (NICE) in *Lactococcus lactis*. *Appl Microbiol Biotechnol* 2005;68(6):705-717.
 40. Vos WMD. Gene cloning and expression in lactic streptococci. *FEMS Microbiol Rev* 1987;46(3):281-295.
 41. de Ruyter PG, Kuipers OP, de Vos WM. Controlled gene expression systems for *Lactococcus lactis* with the food-grade inducer nisin. *Appl Environ Microbiol* 1996;62(10):3662-3667.
 42. Simon D, Chopin A. Construction of a vector plasmid family and its use for molecular cloning in *Streptococcus lacti*. *Biochimie* 1988;70(4):559-566.
 43. Kleerebezem M, Beerthuyzen MM, Vaughan EE, de Vos WM, Kuipers OP. Controlled gene expression systems for lactic acid bacteria: transferable nisin-inducible expression cassettes for *Lactococcus*, *Leuconostoc*, and *Lactobacillus* spp. *Appl Environ Microbiol* 1997;63(11):4581-4584.
 44. Steidler L, Neirynek S, Huyghebaert N, Snoeck V, Vermeire A, Goddeeris B, et al. Biological containment of genetically modified *Lactococcus lactis* for intestinal delivery of human interleukin 10. *Nat Biotechnol* 2003;21(7):785-789.
 45. Bahey-El-Din M, Casey PG, Griffi BT, Gahan CG. Efficacy of a *Lactococcus lactis* Δ pyrG vaccine delivery platform expressing chromosomally integrated hly from *Listeria monocytogenes*. *Bioeng Bugs* 2010;1(1):66-74.
 46. Lin KH, Hsu AP, Shien JH, Chang TJ, Liao JW, Chen JR, et al. Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria. *Vaccine* 2012;30(33):5019-5029.
 47. de Ruyter PG, Kuipers OP, Beerthuyzen MM, van Alen-Boerrigter I, de Vos WM. Functional analysis of promoters in the nisin gene cluster of *Lactococcus lactis*. *J Bacteriol* 1996;178(12):3434-3439.
 48. Mierau I, Leij P, van Swam I, Blommestein B, Floris E, Mond J, et al. Industrial-scale production and purification of a heterologous protein in *Lactococcus lactis* using the nisin-controlled gene expression system NICE: the case of lysostaphin. *Microb Cell Fact* 2005;4:15.
 49. Bron PA, Benchimol MG, Lambert J, Palumbo E, Deghorain M, Delcour J, et al. Use of the *alr* gene as a food-grade selection marker in lactic acid bacteria. *Appl Environ Microbiol* 2002;68(1):5663-5670.
 50. Vos P, Simons G, Siezen RJ, de Vos WM. Primary structure and organization of the gene for a procaryotic, cell envelope-located serine proteinase. *J Biol Chem* 1989;264(23):13579-13585.

Lactococcus as Delivery Vector

51. Novotny R, Scheberl A, Giry-Laterriere M, Messner P, Schäffer C. Gene cloning, functional expression and secretion of the S-layer protein SgsE from *Geobacillus stearothermophilus* NRS 2004/3a in *Lactococcus lactis*. *FEMS Microbiol Lett* 2005;242(1):27-35.
52. van Asseldonk M, Rutten G, Oteman M, Siezen RJ, de Vos WM, Simons G. Cloning of *usp45*, a gene encoding a secreted protein from *Lactococcus lactis* subsp. *lactis* MG1363. *Gene* 1990;95(1):155-160.